

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 August 2001 (16.08.2001)

(10) International Publication Number  
PCT  
WO 01/59064 A3

(51) International Patent Classification <sup>7</sup> :	C07K 2/00,	60/226.279	18 August 2000 (18.08.2000)	US
	C07H 21/04, C12N 21/00, 1/20, 15/00, 5/00, C12P 21/00	60/226.868	22 August 2000 (22.08.2000)	US
(21) International Application Number:	PCT/US01/01342	60/227.182	22 August 2000 (22.08.2000)	US
(22) International Filing Date:	17 January 2001 (17.01.2001)	60/226.681	22 August 2000 (22.08.2000)	US
(25) Filing Language:	English	60/227.009	23 August 2000 (23.08.2000)	US
(26) Publication Language:	English	60/228.924	30 August 2000 (30.08.2000)	US
(30) Priority Data:		60/229.344	1 September 2000 (01.09.2000)	US
		60/229.343	1 September 2000 (01.09.2000)	US
		60/229.287	1 September 2000 (01.09.2000)	US
		60/229.345	1 September 2000 (01.09.2000)	US
		60/229.513	5 September 2000 (05.09.2000)	US
	60/179.065 31 January 2000 (31.01.2000)	60/229.509	5 September 2000 (05.09.2000)	US
	60/180.628 4 February 2000 (04.02.2000)	60/230.438	6 September 2000 (06.09.2000)	US
	60/184.664 24 February 2000 (24.02.2000)	60/230.437	6 September 2000 (06.09.2000)	US
	60/186.350 2 March 2000 (02.03.2000)	60/231.413	8 September 2000 (08.09.2000)	US
	60/189.874 16 March 2000 (16.03.2000)	60/232.080	8 September 2000 (08.09.2000)	US
	60/190.076 17 March 2000 (17.03.2000)	60/231.414	8 September 2000 (08.09.2000)	US
	60/198.123 18 April 2000 (18.04.2000)	60/231.244	8 September 2000 (08.09.2000)	US
	60/205.515 19 May 2000 (19.05.2000)	60/232.081	8 September 2000 (08.09.2000)	US
	60/209.467 7 June 2000 (07.06.2000)	60/231.242	8 September 2000 (08.09.2000)	US
	60/214.886 28 June 2000 (28.06.2000)	60/231.243	8 September 2000 (08.09.2000)	US
	60/215.135 30 June 2000 (30.06.2000)	60/231.968	12 September 2000 (12.09.2000)	US
	60/216.647 7 July 2000 (07.07.2000)	60/232.401	14 September 2000 (14.09.2000)	US
	60/216.880 7 July 2000 (07.07.2000)	60/232.399	14 September 2000 (14.09.2000)	US
	60/217.487 11 July 2000 (11.07.2000)	60/232.400	14 September 2000 (14.09.2000)	US
	60/217.496 11 July 2000 (11.07.2000)	60/232.397	14 September 2000 (14.09.2000)	US
	60/218.290 14 July 2000 (14.07.2000)	60/233.063	14 September 2000 (14.09.2000)	US
	60/220.963 26 July 2000 (26.07.2000)	60/233.064	14 September 2000 (14.09.2000)	US
	60/220.964 26 July 2000 (26.07.2000)	60/233.065	14 September 2000 (14.09.2000)	US
	60/225.757 14 August 2000 (14.08.2000)	60/232.398	14 September 2000 (14.09.2000)	US
	60/225.270 14 August 2000 (14.08.2000)	60/234.223	21 September 2000 (21.09.2000)	US
	60/225.447 14 August 2000 (14.08.2000)	60/234.274	21 September 2000 (21.09.2000)	US
	60/225.267 14 August 2000 (14.08.2000)	60/234.997	25 September 2000 (25.09.2000)	US
	60/225.758 14 August 2000 (14.08.2000)	60/234.998	25 September 2000 (25.09.2000)	US
	60/225.268 14 August 2000 (14.08.2000)	60/235.484	26 September 2000 (26.09.2000)	US
	60/224.518 14 August 2000 (14.08.2000)	60/235.834	27 September 2000 (27.09.2000)	US
	60/224.519 14 August 2000 (14.08.2000)	60/235.836	27 September 2000 (27.09.2000)	US
	60/225.759 14 August 2000 (14.08.2000)	60/236.369	29 September 2000 (29.09.2000)	US
	60/225.213 14 August 2000 (14.08.2000)	60/236.327	29 September 2000 (29.09.2000)	US
	60/225.266 14 August 2000 (14.08.2000)	60/236.370	29 September 2000 (29.09.2000)	US
	60/225.214 14 August 2000 (14.08.2000)	60/236.368	29 September 2000 (29.09.2000)	US

[Continued on next page]

WO 01/59064 A3

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel bladder related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "bladder antigens", and antibodies that immunospecifically bind these polypeptides, and the use of such bladder polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the bladder system, including, but not limited to, the presence of bladder cancer and bladder metastases. More specifically, isolated bladder nucleic acid molecules are provided encoding novel bladder polypeptides. Novel bladder polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human bladder polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the bladder, including bladder cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.



60/236.367	29 September 2000 (29.09.2000)	US	60/251.988	5 December 2000 (05.12.2000)	US
60/237.039	2 October 2000 (02.10.2000)	US	60/251.479	6 December 2000 (06.12.2000)	US
60/237.038	2 October 2000 (02.10.2000)	US	60/251.869	8 December 2000 (08.12.2000)	US
60/237.040	2 October 2000 (02.10.2000)	US	60/251.856	8 December 2000 (08.12.2000)	US
60/237.037	2 October 2000 (02.10.2000)	US	60/251.868	8 December 2000 (08.12.2000)	US
60/236.802	2 October 2000 (02.10.2000)	US	60/251.990	8 December 2000 (08.12.2000)	US
60/239.937	13 October 2000 (13.10.2000)	US	60/251.989	8 December 2000 (08.12.2000)	US
60/239.935	13 October 2000 (13.10.2000)	US	60/254.097	11 December 2000 (11.12.2000)	US
60/241.785	20 October 2000 (20.10.2000)	US	60/259.678	5 January 2001 (05.01.2001)	US
60/241.809	20 October 2000 (20.10.2000)	US			
60/240.960	20 October 2000 (20.10.2000)	US			
60/241.787	20 October 2000 (20.10.2000)	US			
60/241.808	20 October 2000 (20.10.2000)	US			
60/241.221	20 October 2000 (20.10.2000)	US			
60/241.786	20 October 2000 (20.10.2000)	US			
60/241.826	20 October 2000 (20.10.2000)	US			
60/244.617	1 November 2000 (01.11.2000)	US			
60/246.474	8 November 2000 (08.11.2000)	US			
60/246.532	8 November 2000 (08.11.2000)	US			
60/246.476	8 November 2000 (08.11.2000)	US			
60/246.526	8 November 2000 (08.11.2000)	US			
60/246.475	8 November 2000 (08.11.2000)	US			
60/246.525	8 November 2000 (08.11.2000)	US			
60/246.528	8 November 2000 (08.11.2000)	US			
60/246.527	8 November 2000 (08.11.2000)	US			
60/246.477	8 November 2000 (08.11.2000)	US			
60/246.611	8 November 2000 (08.11.2000)	US			
60/246.610	8 November 2000 (08.11.2000)	US			
60/246.613	8 November 2000 (08.11.2000)	US			
60/246.609	8 November 2000 (08.11.2000)	US			
60/246.478	8 November 2000 (08.11.2000)	US			
60/246.524	8 November 2000 (08.11.2000)	US			
60/246.523	8 November 2000 (08.11.2000)	US			
60/249.299	17 November 2000 (17.11.2000)	US			
60/249.210	17 November 2000 (17.11.2000)	US			
60/249.216	17 November 2000 (17.11.2000)	US			
60/249.217	17 November 2000 (17.11.2000)	US			
60/249.211	17 November 2000 (17.11.2000)	US			
60/249.215	17 November 2000 (17.11.2000)	US			
60/249.218	17 November 2000 (17.11.2000)	US			
60/249.208	17 November 2000 (17.11.2000)	US			
60/249.213	17 November 2000 (17.11.2000)	US			
60/249.212	17 November 2000 (17.11.2000)	US			
60/249.207	17 November 2000 (17.11.2000)	US			
60/249.245	17 November 2000 (17.11.2000)	US			
60/249.244	17 November 2000 (17.11.2000)	US			
60/249.297	17 November 2000 (17.11.2000)	US			
60/249.214	17 November 2000 (17.11.2000)	US			
60/249.264	17 November 2000 (17.11.2000)	US			
60/249.209	17 November 2000 (17.11.2000)	US			
60/249.300	17 November 2000 (17.11.2000)	US			
60/249.265	17 November 2000 (17.11.2000)	US			
60/250.391	1 December 2000 (01.12.2000)	US			
60/250.160	1 December 2000 (01.12.2000)	US			
60/256.719	5 December 2000 (05.12.2000)	US			
60/251.030	5 December 2000 (05.12.2000)	US			

(71) **Applicant** (for all designated States except US): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). **BARASH, Steven, C.** [US/US]; 111 Watkins Pond Boulevard #301, Rockville, MD 20850 (US). **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).

(74) **Agents:** **HOOVER, Kenley, K.** et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) **Date of publication of the international search report:**  
14 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US01/01342

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C07K 2/00; C07H 21/04; C12N 21/00, 1/20, 15/00, 5/00; C12P 21/00  
 US CL : 435/69.1, 70.1, 252.3, 320.1, 325; 530, 300, 350; 536/23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 435/69.1, 70.1, 252.3, 320.1, 325; 530, 300, 350; 536/23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	STONE et al. Accession Number AC004049, direct submission, GenEmble database, 31 July 1998. DNA is 82.9% homologous to nucleic acid (SEQ ID'NO:11) claimed in instant application.	1-12, 14-16

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 July 2001 (26.07.2001)

Date of mailing of the international search report

10 SEP 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

BRIDGET E. BUNNER

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01342

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12 and 14-16 (SEQ ID NO: 11 for X and SEQ ID NO: 56 for Y)

**Remark on Protest**  The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01342

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-12 and 14-16, drawn to an isolated nucleic acid of SEQ ID NO: X, a vector, host cell, a method of making a recombinant host cell, an isolated polypeptide of SEQ ID NO: Y encoded by the cDNA sequence of Clone ID NO: Z, and a method of making an isolated polypeptide. Applicant is required to elect only one SEQ ID NO: X and one SEQ ID NO: Y, wherein X and Y are values that correlate to those listed in Table 1A and correspond to one of the cDNA clone IDs, respectively. For example, if SEQ ID NO: 11 is elected for X, this correlates with SEQ ID NO: 56 of Y with clone ID NO: HBAFB96.

Group II, claim(s) 13, drawn to an isolated antibody which binds to a peptide of SEQ ID NO: Y in claim 11. Applicant is required to elect only one SEQ ID NO: Y, wherein Y is a value that correlates to those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example if SEQ ID NO: 57 of Y is elected, this correlates with clone ID NO: HBAGJ74.

Group III, claim(s) 17, drawn to a method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of SEQ ID NO: X in claim 1. Applicant is required to elect only one SEQ ID NO: X, wherein X is a value that correlates to those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example, if SEQ ID NO: 13 of X is elected, this correlates with clone ID NO: HBAGK69.

Group IV, claim(s) 18, drawn to a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising determining the presence or absence of a mutation in the polynucleotide of SEQ ID NO: X in claim 1. Applicant is required to elect only one SEQ ID NO: X, wherein X is a value that correlates to one of those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example, if SEQ ID NO: 14 of X is elected, this correlates with clone ID NO: HBAGU08.

Group V, claim(s) 19, drawn to a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising determining the presence or amount of expression of the polypeptide of SEQ ID NO: Y in claim 11 in a biological sample. Applicant is required to elect only one SEQ ID NO: Y, wherein Y is a value that correlates to one of those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example, if SEQ ID NO: 60 of Y is elected, this correlates with clone ID NO: HBAMC12.

Group VI, claim(s) 20, drawn to a method for identifying a binding partner to the polypeptide of SEQ ID NO: Y in claim 11. Applicant is required to elect only one SEQ ID NO: Y, wherein Y is a value that correlates to one of those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example, if SEQ ID NO: 61 of Y is elected, this correlates with clone ID NO: HBAMC47.

Group VII, claim(s) 21, drawn to the gene corresponding to the cDNA sequence of SEQ ID NO: Y. Applicant is required to elect only one SEQ ID NO: Y, wherein Y is a value that correlates to one of those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example, if SEQ ID NO: 62 of Y is elected, this correlates with clone ID NO: HBAMC68.

Group VIII, claim(s) 22 and 23 drawn to a method of identifying an activity in a biological assay, wherein the method comprises expressing SEQ ID NO: X in a cell, identifying the protein in the supernatant having the activity and the product produced. Applicant is required to elect only one SEQ ID NO: X, wherein X is a value that correlates to one of those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example, if SEQ ID NO: 18 of X is elected, this correlates with clone ID NO: HBAMC92.

Group IX, claim(s) 24, drawn to a method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of SEQ ID NO: Y in claim 11. Applicant is required to elect only one SEQ ID NO: Y, wherein Y is a value that correlates to one of those listed in Table 1A and corresponds to one of the cDNA Clone IDs, respectively. For example, if SEQ ID NO: 64 of Y is elected, this correlates with clone ID NO: HBAMD83.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01342

The inventions listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons: The products including the polynucleotides and polypeptides in Table 1A (Group I) and the gene in Group VII are composed of different coding regions, different sequences and/or impart structural and functional differences and thus do not share a common special technical feature. Furthermore, the antibody of Group II does not share a common special technical feature with the products of Table 1A (Group I) or Group VII. Although the antibody can be used to obtain polypeptides, it can also be used in diagnostic methods. Groups III, IV, V, VI, VIII and IX do not share a special technical feature. These groups are directed to methods that produce different products, recite different elements, and /or achieve different goals. Furthermore, PCT rules do not provide for examination of multiple methods of using the first claimed product.

### **Continuation of B. FIELDS SEARCHED Item 3:**

EAST, DIALOG, EST database, Geneseq database, SPTREMBL database, SwissProt database, PIR database, Issued\_Patents database

search terms: inventors' names, SEQ ID NO: 11, SEQ ID NO: 56